Perspectives in Clinical Research

: 2019  |  Volume : 10  |  Issue : 1  |  Page : 31--33

Indian regulatory update April–October 2018

Amita Bhave1, Lakhvinder Singh Batolar2 
1 Head Regulatory Affairs, Global Drug Development India, Novartis Healthcare Private Ltd., Mumbai, Maharashtra, India
2 General Regulator Affairs Manager, Johnson and Johnson Private Limited, Mumbai, Maharashtra, India

Correspondence Address:
Amita Bhave
Novartis Healthcare Private Limited, Inspire BKC, Part of 601 and 701, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra

This document provides updates in regulatory requirements regarding conduct of clinical trials in India.

How to cite this article:
Bhave A, Batolar LS. Indian regulatory update April–October 2018.Perspect Clin Res 2019;10:31-33

How to cite this URL:
Bhave A, Batolar LS. Indian regulatory update April–October 2018. Perspect Clin Res [serial online] 2019 [cited 2020 Aug 4 ];10:31-33
Available from:;year=2019;volume=10;issue=1;spage=31;epage=33;aulast=Bhave;type=0